INmune Bio (INMB)

• Market cap: $143M
• 1 day: -4.02%
• 5 days: 11.40%
• 1 month: 29.52%
• 3 months: 29.00%
• 6 months: -28.96%
• Year to date: 30.83%
• 1 year: -43.17%
• 5 years: 13.96%
• 10 years: -19.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Employees: 17

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

550% more call options, than puts

Call options by funds: $2M | Put options by funds: $308K

300% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 7

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

16% more funds holding

Funds holding: 56 [Q2] → 65 (+9) [Q3]

0.91% more ownership

Funds ownership: 23.26% [Q2] → 24.17% (+0.91%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

29% less capital invested

Capital invested by funds: $40.6M [Q2] → $28.9M (-$11.7M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 210% upside
• Avg. target: $20 210% upside
• High target: $20 210% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Alliance Global Partners James Molloy 20% 1-year accuracy 2 / 10 met price target

210% upside $20

Buy Initiated

21 Oct 2024